Great Point Partners LLC: 13F holdings, Q2 2026
Hedge fund · SEC EDGAR filings (CIK 1281446) · Explore on the interactive board
Great Point Partners LLC disclosed 37 US equity positions worth $424.4m in its Q2 2026 13F filing (holdings as of June 30, 2026, filed August 14, 2026). Its largest position is VOR at 7.4% of the reported book, followed by ABVX, VERA. The top ten holdings are 53.6% of the book, and the portfolio behaves like about 25 equal-weight positions. Versus the prior filing it opened 11 new positions, added to 7, reduced 9 and exited 13. Note: this manager's most recent filing is 3934 quarters behind the newest quarter on file, so these figures are history rather than current positioning.
What does Great Point Partners LLC own? Top holdings as of June 30, 2026
Change is measured in shares against the previous filing (Q1 2026), so price moves do not read as decisions. This quarter: 11 new, 7 added, 9 reduced, 13 exited.
| # | Stock | Sector | Weight | Value | Shares | Δ shares | Action |
|---|---|---|---|---|---|---|---|
| 1 | VOR VOR BIOPHARMA INC | Healthcare | 7.4% | $31.3m | 1,700,000 | -3% | reduced |
| 2 | ABVX ABIVAX SA | Healthcare | 6.4% | $27.2m | 204,314 | – | new |
| 3 | VERA VERA THERAPEUTICS INC | Healthcare | 6.1% | $25.8m | 600,836 | 201% | added |
| 4 | ZURA ZURA BIO LTD | Healthcare | 5.9% | $24.9m | 4,215,930 | 0% | held |
| 5 | ALMS ALUMIS INC | Healthcare | 5.7% | $24.1m | 856,061 | 0% | held |
| 6 | SOL-GEL TECHNOLOGIES LTD | 4.8% | $20.3m | 274,363 | 0% | held | |
| 7 | DFTX DEFINIUM THERAPEUTICS INC | Healthcare | 4.7% | $20.0m | 425,000 | – | new |
| 8 | ANNX ANNEXON INC | Healthcare | 4.7% | $20.0m | 3,500,000 | 40% | added |
| 9 | ORKA ORUKA THERAPEUTICS INC | Healthcare | 4.1% | $17.4m | 183,330 | 0% | held |
| 10 | MLTX MOONLAKE IMMUNOTHERAPEUTICS | Healthcare | 3.9% | $16.7m | 855,813 | 71% | added |
| 11 | SGMT SAGIMET BIOSCIENCES INC | Healthcare | 3.7% | $15.7m | 2,029,933 | – | new |
| 12 | CTNM CONTINEUM THERAPEUTICS INC | 3.6% | $15.1m | 921,481 | 15% | added | |
| 13 | IMMX IMMIX BIOPHARMA INC | 3.1% | $13.2m | 1,277,642 | 265% | added | |
| 14 | CLYM CLIMB BIO INC | Healthcare | 3.1% | $13.0m | 1,000,000 | -25% | reduced |
| 15 | AMLX AMYLYX PHARMACEUTICALS INC | Healthcare | 3.0% | $12.6m | 700,000 | -60% | reduced |
| 16 | NKTR NEKTAR THERAPEUTICS | Healthcare | 2.9% | $12.2m | 175,000 | -45% | reduced |
| 17 | NGNE NEUROGENE INC | 2.6% | $11.1m | 352,180 | -30% | reduced | |
| 18 | LB PHARMACEUTICALS INC | 2.4% | $10.3m | 317,221 | 6% | added | |
| 19 | IRD OPUS GENETICS INC | 1.9% | $8.1m | 1,970,187 | 507% | added | |
| 20 | EPRX EUPRAXIA PHARMACEUTICALS INC | 1.9% | $7.9m | 1,200,000 | 0% | held | |
| 21 | DRUG BRIGHT MINDS BIOSCIENCES INC | Healthcare | 1.8% | $7.7m | 109,603 | -50% | reduced |
| 22 | INFLARX NV | 1.6% | $6.8m | 3,046,557 | – | new | |
| 23 | RLMD RELMADA THERAPEUTICS INC | Healthcare | 1.4% | $5.8m | 842,106 | 0% | held |
| 24 | JATT II ACQUISITION CORP | 1.3% | $5.7m | 500,000 | – | new | |
| 25 | CGEM CULLINAN THERAPEUTICS INC | Healthcare | 1.3% | $5.5m | 300,000 | 0% | held |
| 26 | ALT ALTIMMUNE INC | Healthcare | 1.2% | $5.3m | 1,741,232 | – | new |
| 27 | AMANAT ACQUISITION CORP | 1.2% | $5.1m | 500,000 | – | new | |
| 28 | RZLT REZOLUTE INC | 1.2% | $4.9m | 951,809 | 0% | held | |
| 29 | SLN SILENCE THERAPEUTICS PLC | 1.2% | $4.9m | 450,000 | -56% | reduced | |
| 30 | PALI PALISADE BIO INC | Healthcare | 1.1% | $4.8m | 2,284,819 | -33% | reduced |
| 31 | EVMN EVOMMUNE INC | 1.0% | $4.3m | 325,000 | 0% | held | |
| 32 | SCYX SCYNEXIS INC | 0.9% | $3.8m | 944,292 | – | new | |
| 33 | ELVN ENLIVEN THERAPEUTICS INC | Healthcare | 0.8% | $3.6m | 70,000 | – | new |
| 34 | HUMA HUMACYTE INC | 0.7% | $2.9m | 3,750,000 | 0% | held | |
| 35 | RNTX REIN THERAPEUTICS INC | 0.6% | $2.7m | 2,575,000 | – | new | |
| 36 | DBVT DBV TECHNOLOGIES S A | 0.6% | $2.6m | 156,906 | – | new | |
| 37 | PROMIS NEUROSCIENCES INC | 0.3% | $1.1m | 86,150 | -77% | reduced |
What did Great Point Partners LLC sell? Positions exited since the previous filing
| Stock | Prior weight | Prior value |
|---|---|---|
| APGE APOGEE THERAPEUTICS INC | 26.5% | $31.5m |
| 4XC1 KALVISTA PHARMACEUTICALS INC | 11.4% | $13.6m |
| IMVT IMMUNOVANT INC | 11.4% | $13.6m |
| JBIO JADE BIOSCIENCES INC | 11.4% | $13.6m |
| ZBIO ZENAS BIOPHARMA INC | 8.6% | $10.2m |
| CMPX COMPASS THERAPEUTICS INC | 6.0% | $7.1m |
| SCYX SCYNEXIS INC | 5.8% | $6.9m |
| CNTX CONTEXT THERAPEUTICS INC | 4.9% | $5.9m |
| UNCY UNICYCIVE THERAPEUTICS INC | 4.4% | $5.2m |
| TENX TENAX THERAPEUTICS INC | 4.4% | $5.2m |
| PHVS PHARVARIS N V | 2.0% | $2.3m |
| AVTX AVALO THERAPEUTICS INC | 1.6% | $1.9m |
| ALKS ALKERMES PLC | 1.5% | $1.8m |
Sector mix
| Sector | Weight |
|---|---|
| Healthcare | 69.1% |
Sectors cover positions whose ticker resolved to a sector; the remainder is unclassified, not cash.
Filing history
How concentrated is Great Point Partners LLC's portfolio?
Across every quarter Great Point Partners LLC has filed, its median largest position is 7.5% of the book and its median top-ten weight is 53.6%, which WhaleCreep classifies as concentrated (the gate is a median largest position of 5%). Of 12.0 completed holding spells, the median lasted 1.0 quarters; 37.0 positions are still open and their final length is unknown.